Precision BioSciences, Inc. (DTIL) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.04
↓-47% vs avg
5yr avg: 1.95
30Y Low0.5·High9.8
ROE
↓
-62.7%
↓+20% vs avg
5yr avg: -78.1%
30Y Low-155%·High19%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DTIL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Precision BioSciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $96M | $53M | $26M | $42M | $105M | $434M | $434M | $583M | — | — | — |
| Enterprise Value | $14M | $-28658516 | $-29626299 | $-43346615 | $-60016821 | $300M | $355M | $402M | — | — | — |
| P/E Ratio → | -2.06 | — | 3.66 | — | — | — | — | — | — | — | — |
| P/S Ratio | 2.80 | 1.56 | 0.38 | 0.86 | 4.17 | 3.76 | 17.87 | 26.23 | — | — | — |
| P/B Ratio | 1.04 | 0.58 | 0.47 | 2.23 | 1.73 | 4.76 | 9.77 | 4.22 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DTIL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.84 | -0.43 | -0.89 | -2.39 | 2.59 | 14.60 | 18.10 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | -3.31 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
DTIL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Precision BioSciences, Inc. earns an operating margin of -152.2%. Operating margins have compressed from -89.8% to -152.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -62.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.0% | 92.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -152.2% | -152.2% | -38.1% | -89.8% | -248.3% | -34.1% | -452.2% | -392.1% | -440.2% | -338.9% | -125.8% |
| Net Profit Margin | -136.0% | -136.0% | 10.4% | -125.8% | -444.8% | -26.5% | -448.9% | -417.6% | -423.0% | -325.4% | -117.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -62.7% | -62.7% | 19.0% | -154.7% | -147.3% | -45.1% | -119.3% | -104.2% | -677.5% | — | — |
| ROA | -32.1% | -32.1% | 4.8% | -30.8% | -49.7% | -16.9% | -56.6% | -49.7% | -43.6% | -24.7% | -8.4% |
| ROIC | -726.2% | -726.2% | — | — | — | — | — | — | — | — | — |
| ROCE | -39.1% | -39.1% | -22.6% | -30.3% | -35.2% | -27.8% | -69.6% | -52.4% | -51.0% | -28.6% | -9.8% |
DTIL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $111M exceeds total debt of $29M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.31 | 0.31 | 0.53 | 1.66 | 0.41 | 0.10 | 0.24 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.89 | -0.99 | -4.53 | -2.72 | -1.48 | -1.78 | -1.31 | -2.58 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -1.04 |
| Interest Coverage | -36.67 | -36.67 | 5.02 | -18.07 | -64.62 | -230.83 | — | -509.31 | — | — | — |
Net cash position: cash ($111M) exceeds total debt ($29M)
DTIL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Precision BioSciences, Inc.'s current ratio of 13.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.73x to 13.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.32 | 13.32 | 6.34 | 2.73 | 3.34 | 4.50 | 2.46 | 7.19 | 8.22 | 6.99 | 11.32 |
| Quick Ratio | 13.32 | 13.32 | 6.34 | 2.73 | 3.34 | 4.50 | 2.46 | 7.19 | 8.22 | 6.99 | 11.32 |
| Cash Ratio | 12.97 | 12.97 | 5.76 | 2.33 | 3.18 | 3.99 | 2.10 | 6.72 | 7.33 | 6.82 | 11.20 |
| Asset Turnover | — | 0.22 | 0.50 | 0.30 | 0.11 | 0.55 | 0.16 | 0.09 | 0.08 | 0.09 | 0.07 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 9.02 | 95.87 | 10.47 | 1.54 | 150.30 | 15.84 | 17.54 | 1.24 | 20.08 |
DTIL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Precision BioSciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 27.3% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $13M | $7M | $4M | $3M | $2M | $2M | $1M | $2M | $1M | $17M |
Peer Comparison
Compare DTIL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DTILYou | $96M | -2.1 | — | — | 92.0% | -152.2% | -62.7% | -726.2% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 SANA | $918M | -3.0 | — | — | — | — | -99.2% | -86.1% | — |
 ALLO | $521M | -2.6 | — | — | — | — | -53.4% | -41.7% | — |
 PGEN | $1B | -8.8 | — | — | -8.7% | -3440.2% | -160.8% | -152.8% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See DTIL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DTIL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DTIL vs BEAM
Side-by-side business, growth, and profitability comparison vs Beam Therapeutics Inc..
Start ComparisonDTIL — Frequently Asked Questions
Quick answers to the most common questions about buying DTIL stock.
What is Precision BioSciences, Inc.'s P/E ratio?
Precision BioSciences, Inc.'s current P/E ratio is -2.1x. The historical average is 3.7x.
What is Precision BioSciences, Inc.'s ROE?
Precision BioSciences, Inc.'s return on equity (ROE) is -62.7%. The historical average is -87.7%.
Is DTIL stock overvalued?
Based on historical data, Precision BioSciences, Inc. is trading at a P/E of -2.1x. Compare with industry peers and growth rates for a complete picture.
What are Precision BioSciences, Inc.'s profit margins?
Precision BioSciences, Inc. has 92.0% gross margin and -152.2% operating margin.